NEC Publishes Design Blueprints for SARS-CoV-2 Vaccines Using its Artificial Intelligence Technology
- Accelerating efforts to create a vaccine to combat the COVID-19 pandemic to benefit the global population -
TOKYO, Apr 23, 2020 - (JCN Newswire) - NEC Corporation (TSE: 6701) today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE). These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.
During the analysis, which is published at bioRxiv, the team analyzed thousands of sequences from the SARS-CoV-2 virus (responsible for causing COVID-19) and identified epitopes (potential vaccine targets) for the 100 most frequent HLA alleles (diverse immunological makeup) in the global population. The prediction algorithms scanned for epitopes across the entire repertoire of proteins in SARS-CoV-2, not only the spike surface protein that gives this family of coronavirus its name. The team then used this data to identify "hotspots" in the viral proteome that contained overlapping and co-located epitopes from multiple HLA-alleles. The optimal constellation of "hotspots" was then selected by their algorithms to generate the optimal immune response with the broadest coverage of the human population, whilst prioritizing hotspots that occurred in conserved regions of the viral proteome. These conserved regions are less likely to mutate in future strains. In addition, hotspots containing viral epitopes that had significant similarity with human proteins, especially those expressed in critical organs, were removed from the vaccine design blueprints to avoid adverse effects.
The analysis demonstrates the significant capabilities of the NEC Group to leverage their AI platforms to design blueprints for a vaccine that is safe and efficacious in a global population and could address the current and future divergent strains of the SARS-CoV-2 virus.
NEC is now publishing this research to support scientific advancements in the field and is ready to start partnering efforts to pursue the development of an effective vaccine targeting the global population.
"We are pleased that NEC's AI technology can contribute to the resolution of serious problems facing the world today. As a company that seeks to enhance the well-being of society, NEC will continue to capitalize on research and development that maximizes the strengths of our AI technology to help prevent the spread of COVID-19. In collaboration with companies and institutions around the world, we aim to enable people to live their daily lives with as much safety and security as possible," said Motoo Nishihara, Executive Vice President and Chief Technology Officer at NEC.
NEC OncoImmunity AS
"It has been exhilarating hard work between our CEO, Dr. Richard Stratford, the entire team at NEC OncoImmunity and our colleagues in the NEC Group to adapt our NEC Immune Profiler technology from its current cancer focus and quickly make it applicable to infectious diseases to help deal with the COVID-19 threat. It is encouraging that our AI and bioinformatics platform can design vaccine blueprints that have the potential to induce a broad immune response, that may not only be protective for the global population, but also stimulate a long-lived memory immune responses against SARS-CoV-2 and its future mutated versions," said Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity and the lead corresponding author in the paper.
NEC Laboratories Europe GmbH
"We have been repurposing our algorithms originally designed for predicting immune responses in individual cancer patients to scale to large population targets for infectious diseases. The in-silico validation of our algorithms takes into account the genetic background of humans across all continents. Now demonstrating that our predictions can contribute to the worldwide efforts to stop COVID-19 is of utmost importance. We have already started discussions with partner organizations for wet-lab validation activities. This is an important step towards the development of an effective vaccine for the global population," said Dr. Saverio Niccolini, General Manager of the Data Science and System Platform Division at NEC Laboratories Europe GmbH.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
About NEC OncoImmunity AS
NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software called as the NEC Immune Profiler, which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. The NEC Immune Profiler can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit OncoImmunity AS at http://www.oncoimmunity.com/.
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency, and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.
Source: NEC Corporation
Sectors: BioTech, AI
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST
Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST
DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST
Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST
Mitsubishi Motors Announces Production, Sales and Export Figures for April 2020
May 28, 2020 19:09 JST
Honda Sets Monthly Records for Automobile Production in China
May 28, 2020 18:52 JST
Mazda Production and Sales Results for April 2020
May 28, 2020 16:46 JST
Mazda Joins IP Open Access Declaration Against Covid-19
May 28, 2020 16:28 JST
Toyota Releases Sales, Production, and Export Results for April 2020
May 28, 2020 13:56 JST
Fujitsu Accelerates Digital Transformation with Flexible, Scale-out Software-Defined Storage ETERNUS Data Services Platform
May 28, 2020 11:26 JST
Alliance New Cooperation Business Model to Support Member-Company Competitiveness and Profitability
May 27, 2020 18:28 JST
eK X and eK Wagon Achieve Top Ratings for Preventive and Collision Safety Performance in JNCAP
May 27, 2020 15:31 JST
2019 JNCAP Assessment on Toyota Vehicles Announced
May 27, 2020 14:07 JST
Fujitsu Launches 14 New Models of Enterprise Notebooks, Tablets and Workstations Optimized for Remote Work
May 26, 2020 11:10 JST
Fujitsu Develops AI-Video Recognition Technology to Promote Hand Washing Etiquette and Hygiene in the Workplace
May 26, 2020 10:34 JST
Mitsubishi Motors Joins OPEN COVID-19 DECLARATION
May 26, 2020 09:34 JST
Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC
May 25, 2020 10:44 JST
Mazda Begins Providing, Virtual Racing Car, Mazda RX-Vision GT3 Concept Online
May 22, 2020 14:26 JST
'e5 Consortium' Established to Promote Zero-Emission Electric Vessel
May 21, 2020 15:34 JST